SAB Biotherapeutics confirms neutralising antibodies to SARS-CoV-2 and begins clinical manufacturing of novel Covid-19 therapeutic candidate

SAB Biotherapeutics has started clinical manufacturing of novel Covid-19 therapeutic candidate. (Credit: dianakuehn30010 from Pixabay)